Diagnosis and Management of Castleman Disease

Author:
Jeremy S. Abramson
Search for other papers by Jeremy S. Abramson in
Current site
Google Scholar
PubMed Close
 MD, MMSc
Volume/Issue:
Volume 17: Issue 11.5
Online Publication Date:
Nov 2019
DOI:
https://doi.org/10.6004/jnccn.2019.5037
Restricted access

Castleman disease is a heterogeneous nonmalignant lymphoproliferative disorder. Major distinctions include unicentric versus multicentric presentation; hyaline vascular, plasmacytic, or mixed pathology; and HHV8-associated (typically HIV-positive) versus idiopathic disease. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Jeremy S. Abramson stated that rituximab is preferred as initial therapy for HHV8-positive disease, and chemotherapy can be added for patients with fulminant disease (antiretrovirals should always be used as well for those who are HIV-positive). Siltuximab is the preferred frontline therapy for idiopathic disease.

Disclosures: Dr. Abramson has disclosed that he receives consulting fees from AbbVie, Inc., Bayer HealthCare, Celgene Corporation, EMD Serono, Genentech, Inc., Janssen Pharmaceutica Products, LP, Karyopharm Therapeutics, Kite Pharma, and Roche Laboratories, Inc.

Correspondence: Jeremy S. Abramson, MD, MMSc, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114. Email: jabramson@mgh.harvard.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB trial. J Clin Oncol 2007;25:3350–3356.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Gérard L, Michot JM, Burcheri S, et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood 2012;119:2228–2233.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood 2014;124:3544–3552.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2014;15:966–974.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood 2013;122:4189–4198.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Zelenetz AD, Gordon LI, Abramson JS, et al. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Version 5.2019. To view the most recent version, visit NCCN.org. Accessed October 15, 2019.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood 2019;133:1720–1728.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2019 by the National Comprehensive Cancer Network 2019
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
01 Nov 2019
Online Publication Date:
Nov 2019

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 10950 2307 417
PDF Downloads 6467 585 15
EPUB Downloads 0 0 0